(Q41452415)

English

An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge

scientific article published on 22 August 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Yersinia pestis

0 references

vector-borne disease

0 references

vesicular stomatitis

1 reference

based on heuristic

inferred from title

7

object named as

David S Perlin

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

author name string

Amy Palin

1

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Anasuya Chattopadhyay

2

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Steven Park

3

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Guillaume Delmas

4

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Rema Suresh

5

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Svetlana Senina

6

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

John K Rose

8

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

language of work or name

0 references

publication date

22 August 2006

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

741-750

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Molecular insights into the history of plague

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Yersinia pestis--etiologic agent of plague

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Yersiniosis. II: The pathogenesis of Yersinia infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Multidrug resistance in Yersinia pestis mediated by a transferable plasmid

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Prevention and treatment of bacterial diseases caused by bacterial bioterrorism threat agents

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Yersinia pestis (plague) vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Antibody against V antigen prevents Yop-dependent growth of Yersinia pestis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Role of fraction 1 antigen of Yersinia pestis in inhibition of phagocytosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Effects of Fraction I from Yersinia pestis on Phagocytosis In Vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Relationship between virulence and immunity as revealed in recent studies of the F1 capsule of Yersinia pestis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

The V-antigen of Yersinia is surface exposed before target cell contact and involved in virulence protein translocation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Molecular analysis of lcrGVH, the V antigen operon of Yersinia pestis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Yersinia V-antigen exploits toll-like receptor 2 and CD14 for interleukin 10-mediated immunosuppression

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Protection studies following bronchopulmonary and intramuscular immunisation with yersinia pestis F1 and V subunit vaccines coencapsulated in biodegradable microspheres: a comparison of efficacy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

A single dose sub-unit vaccine protects against pneumonic plague

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Local and systemic immune response to a microencapsulated sub-unit vaccine for plague

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Protection against plague afforded by immunisation with DNA vaccines optimised for expression of the Yersinia pestis V antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Co-immunisation with a plasmid DNA cocktail primes mice against anthrax and plague.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Recombinant vesicular stomatitis viruses from DNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Cell-mediated protection against pulmonary Yersinia pestis infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Generation of protective immune responses to plague by mucosal administration of microsphere coencapsulated recombinant subunits

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Interleukin-10 and inhibition of innate immunity to Yersiniae: roles of Yops and LcrV (V antigen)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

LcrV plague vaccine with altered immunomodulatory properties

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

Virulence genes regulated at the transcriptional level by Ca2+ in Yersinia pestis include structural genes for outer membrane proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

based on heuristic

inferred from DOI database lookup

Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

based on heuristic

inferred from DOI database lookup

Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

based on heuristic

inferred from DOI database lookup

Passive immunity to yersiniae mediated by anti-recombinant V antigen and protein A-V antigen fusion peptide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

based on heuristic

inferred from DOI database lookup

Suppression of cytokines in mice by protein A-V antigen fusion peptide and restoration of synthesis by active immunization.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.08.010

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2006.08.010

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41452415&oldid=2097900347"